Ignite Creation Date:
2024-05-05 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00409383
Status:
UNKNOWN
Last Update Posted:
2011-11-06
First Post:
2006-12-07
Brief Title:
Abraxane and Temodar Plus Genasense in Advanced Melanoma
Sponsor:
Genta Incorporated
Organization:
Genta Incorporated
Study Overview
Official Title:
A Pilot Study of Abraxane Albumin-bound Paclitaxel and Temodar Temozolomide Plus Genasense Oblimersen Sodium in Subjects With Advanced Melanoma The ATG Study
Status:
UNKNOWN
Status Verified Date:
2010-07
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to evaluate the safety efficacy pharmacokinetics and pharmacodynamics of combination treatment with Temodar Genasense and Abraxane in chemotherapy-naïve subjects with advanced melanoma and normal lactate dehydrogenase LDH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None